Do You Need Lab Work Before Getting a GLP-1 Prescription?

Some GLP-1 telehealth providers require blood work before prescribing. Others don't. The difference isn't always about clinical quality — it's about risk tolerance, patient population, and how the provider structures follow-up care. Here's what the evidence says about when labs are medically necessary versus clinically optional.

What the FDA Labels Say

Neither the semaglutide (Wegovy) nor tirzepatide (Zepbound) prescribing information requires specific lab work prior to initiation. The labels list contraindications (MTC/MEN2 history, pancreatitis) and precautions (kidney impairment, diabetic retinopathy, gallbladder disease) — but these are assessed through medical history, not mandatory labs.

This means a physician can legally and appropriately prescribe GLP-1 medication based on a thorough medical history and intake assessment alone. Requiring labs is a clinical judgment call, not an FDA mandate.

When Labs Are Strongly Recommended

While not universally required, there are situations where skipping pre-treatment labs would be clinically irresponsible. If you have type 2 diabetes or are on insulin, baseline A1C, fasting glucose, and renal function (eGFR, creatinine) are essential for safe dose management. GLP-1 medications potently lower blood sugar, and starting without knowing your baseline creates hypoglycemia risk.

If you have known kidney disease (any stage), renal function tests should be current. GLP-1 medications aren't directly nephrotoxic, but GI side effects (nausea, vomiting, diarrhea) can cause dehydration that worsens renal function in vulnerable patients.

If you have thyroid nodules or a family history of thyroid cancer, a baseline thyroid panel (TSH, free T4) and potentially calcitonin levels are prudent — not because GLP-1s are proven to cause thyroid cancer in humans, but because the rodent signal warrants monitoring in at-risk populations.

The Standard Pre-Treatment Panel

When providers do order labs, the typical panel includes a comprehensive metabolic panel (CMP) covering liver and kidney function, electrolytes, and fasting glucose; A1C for diabetes screening; a lipid panel (total cholesterol, LDL, HDL, triglycerides); and thyroid function (TSH). Some providers add vitamin D, B12, and iron/ferritin — nutrients that can become deficient during rapid weight loss when caloric intake drops.

This panel costs $50–150 through direct-to-consumer lab services (Quest, Labcorp walk-in) and is often covered by insurance when ordered by a physician. Many GLP-1 telehealth platforms bundle lab orders into their service — either partnering with national labs or accepting outside results.

Providers That Require Labs vs Those That Don't

Higher-touch platforms — typically those charging $250+/month — tend to require baseline labs and follow-up labs at 3 and 6 months. This is arguably better clinical practice, as it establishes baseline metrics for monitoring progress and detecting complications early.

Lower-cost platforms and those focused on speed often make labs optional or "recommended but not required." This isn't inherently inferior — for a healthy 35-year-old with no medical history who just wants to lose weight, the clinical value of baseline labs is modest. The risk-benefit calculation changes for older patients, those with existing conditions, and anyone on concurrent medications.

Follow-Up Labs: When and What

Post-initiation lab monitoring is where the real clinical value lies. Most guidelines suggest repeating the baseline panel at 3 months (to check for medication effects on liver, kidney, and thyroid function), 6 months (to assess metabolic improvement — A1C, lipids), and annually thereafter for maintenance patients. If you're losing weight rapidly (>2% per week), earlier monitoring may be warranted to check for nutritional deficiencies and dehydration markers.